Mineralys Therapeutics, Inc. (MLYS)
25.29
-0.36
(-1.40%)
USD |
NASDAQ |
Aug 24, 16:00
25.29
0.00 (0.00%)
After-Hours: 20:00
Mineralys Therapeutics Shareholders Equity (Quarterly) : 550.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 550.92M |
| March 31, 2026 | 638.14M |
| December 31, 2025 | 646.69M |
| September 30, 2025 | 576.43M |
| June 30, 2025 | 313.55M |
| March 31, 2025 | 341.56M |
| December 31, 2024 | 191.26M |
| September 30, 2024 | 236.93M |
| June 30, 2024 | 290.10M |
| March 31, 2024 | 328.04M |
| Date | Value |
|---|---|
| December 31, 2023 | 241.15M |
| September 30, 2023 | 264.01M |
| June 30, 2023 | 285.01M |
| March 31, 2023 | 295.88M |
| December 31, 2022 | 106.38M |
| September 30, 2022 | 115.23M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 6.071M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 348.30M |
| Evommune, Inc. | 277.59M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 667.85M |
| Total Liabilities (Quarterly) | 116.94M |
| Debt to Equity Ratio | 0.1772 |
| Current Ratio | 34.46 |
| Net Debt Paydown Yield | -0.82% |